BioSpace News Archive

Hoth Therapeutics, Inc., announced today that it has entered into two contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), for process development and manufacturing of the active pharmaceutical ingredient (API) and formulation of drug product for the continued development and commercialization of HT-KIT.

Ascentage Pharma (6855.HK), today announced a clinical trial collaboration and supply agreement with Pfizer Inc. to study the combination of Ascentage Pharma’s lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, in combination with Pfizer’s IBRANCE® (palbociclib).

DURECT Corporation (Nasdaq: DRRX) today announced that Suthat Liangpunsakul, M.D. will present a poster at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting® 2021 to be held virtually November 12-15, 2021.

Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today the expansion of its program for investigational H100, a novel patented non-invasive topical treatment under development for Peyronie’s disease.

Melzi Surgical, a surgical device company dedicated to creating innovative technologies that improve patient outcomes while reducing hospital expenses, announced a report evaluating the Company’s lead product, the Sharps Finder™.

Investigators, led by CancerCare Manitoba researchers and BioMark collaborators, Drs. Donald W. Miller and Marshall Pitz, will be presenting 2 posters on ongoing pre-clinical and clinical research work related to a novel treatment monitoring tool and a potential therapeutic target for glioblastoma (GBM) patients using proprietary brain delivery mechanism.

With the recent expansion into the United States, I-MED Pharma USA is proud to announce the appointment of Brent Jones to Chief Commercial Officer effective November 1st, 2021.

The Vistria Group, LP (“Vistria”) announced the acquisition of BioCare, Inc. (the “Company” or “BioCare”), a leading specialty pharmaceutical distribution partner that provides distribution, specialty pharmacy and logistics services.

Last week, at its first-ever Cost of Care Summit, the American Diabetes Association® (ADA) shared the results of a new study on Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race.

Organon (NYSE: OGN) is pleased to announce NEXPLANON® (etonogestrel extended-release subdermal implant) public listing in Quebec under the Régie de l’assurance maladie du Québec (RAMQ) as of November 10.